Sugi Predict

Sugi Predict / Compounds / SCHEMBL478774

SCHEMBL478774

SCHEMBL478774

CC(C)(C)OC(=O)NC(Cc1ccncc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 1/20 0.62
▸ ITGB3 P05106 2/20 0.59
▸ ITGA2B P08514 2/20 0.59
▸ CTSS P25774 6/20 0.55
▸ CTSK P43235 5/20 0.55
▸ CTSL P07711 1/20 0.55
▸ CTSB P07858 1/20 0.55
▸ ITGA4 P13612 2/20 0.53
▸ ITGB7 P26010 2/20 0.53
▸ PTPN1 P18031 2/20 0.53
▸ PPARA Q07869 4/20 0.51
▸ PPARG P37231 3/20 0.51
▸ APP P05067 1/20 0.50
▸ ITGB1 P05556 1/20 0.49
▸ ITGAV P06756 1/20 0.49
▸ ITGB5 P18084 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ PPARD Q03181 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16658 1.00 ACE (0.62) ACEITGB3ITGA2BCTSSCTSK
SCHEMBL3338649 1.00 ACE (0.62) ACEITGB3ITGA2BCTSSCTSK
SCHEMBL2310637 0.92 CTSS (0.60) ACEITGB3ITGA2BCTSSCTSK
SCHEMBL2715763 0.92 CTSS (0.60) ACEITGB3ITGA2BCTSSCTSK
SCHEMBL2310645 0.92 CTSS (0.60) ACEITGB3ITGA2BCTSSCTSK
SCHEMBL3824787 0.91 ACE (0.54) ACEITGB3ITGA2BCTSSCTSK
SCHEMBL31407761 0.90 ITGB3 (0.61) ACEITGB3ITGA2BCTSSCTSK
SCHEMBL7436985 0.89 CTSS (0.53) ACEITGB3ITGA2BCTSSCTSK
SCHEMBL6749429 0.89 CTSS (0.52) ACEITGB3ITGA2BCTSSCTSK
SCHEMBL13538229 0.88 KLK5 (0.57) ACEITGB3ITGA2BCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479927-B2 Compounds comprising cleavable linker and uses thereof INTOCELL, INC. (KR) 2025-11-25 — — US disclosed
US-20250162989-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2025-05-22 — — US disclosed
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2025-01-07 — — US disclosed
US-12029739-B2 SHP2 inhibitor and use thereof KANAPH THERAPEUTICS INC. (KR) 2024-07-09 — — US disclosed
US-20240189306-A1 SHP2 INHIBITOR AND USE THEREOF KANAPH THERAPEUTICS INC. (KR) 2024-06-13 — — US disclosed
EP-4368625-A1 SHP2 INHIBITOR AND USE THEREOF Kanaph Therapeutics Inc. (KR) 2024-05-15 — — EP disclosed
CN-117916242-A SHP2 inhibitors and uses thereof 治纳辅医药科技有限公司 2024-04-19 — — CN disclosed
US-11952365-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 — — US disclosed
CN-117836270-A USP30 inhibitors and uses thereof 文森雷生物科学股份有限公司 2024-04-05 — — CN disclosed
EP-3568390-B1 SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) 2024-03-06 — — EP disclosed
US-20040147520-A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 — — US disclosed
WO-2003093245-A1 SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS ELAN PHARMACEUTICALS, INC. (US) 2003-11-13 — — WO disclosed
US-6432980-B1 PREVENTION OF COCCIDIOSIS IN POULTRY MERCK & CO., INC. 2002-08-13 — — US disclosed
EP-0509354-B1 Amino acid derivatives HOFFMANN LA ROCHE (CH) 2000-08-23 — — EP disclosed
US-5393875-A Hypotensive, cardiotonic and antiischemic agents HOFFMANN-LA ROCHE INC. (US) 1995-02-28 — — US disclosed
EP-0527764-A1 PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY Beecham Group p.l.c. (GB) 1993-02-24 — — EP disclosed
EP-0509354-A2 Amino acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1992-10-21 — — EP disclosed
WO-1991015507-A1 PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY BEECHAM GROUP PLC (GB) 1991-10-17 — — WO disclosed
US-4940702-A Cephem compounds BEECHAM GROUP P.L.C. (GB) 1990-07-10 — — US disclosed
EP-0211656-A2 Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1987-02-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 ACE 2233/4885ITGB3 4873/4885ITGA2B 4831/4885
US-11952365-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 ACE 7/4885ITGB3 4589/4885ITGA2B 4558/4885
US-20240189306-A1 SHP2 INHIBITOR AND USE THEREOF PTPN1, PTPN5, PTPN2 ACE 1077/4885ITGB3 4763/4885ITGA2B 4540/4885
US-12479927-B2 Compounds comprising cleavable linker and uses thereof VIP, ANTXR2, TNFRSF9 ACE 1594/4885ITGB3 2870/4885ITGA2B 1868/4885
US-12029739-B2 SHP2 inhibitor and use thereof PTPN1, PTPN5, PTPN2 ACE 1077/4885ITGB3 4763/4885ITGA2B 4540/4885
US-20040147520-A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists BDKRB2, BDKRB1, PDXK ACE 66/4885ITGB3 3661/4885ITGA2B 3067/4885
US-20250162989-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 ACE 2383/4885ITGB3 4634/4885ITGA2B 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.